|
Published
|
Volume-Issue
|
Title
|
Total: 77 |
11/2009 |
9-5 |
Aggressive RAAS Blockade and the Kidney after ONTARGET
PHILIP MCFARLANE, MD, PHD, FRCP(C)
Drugs that block the renin-angiotensin-aldosterone system (RAAS) are the most commonly-
used antihypertensives in Canada, with a combined prescription rate of about 1000/10 000 population. Angiotensin-converting enzyme (ACE) inhibitors and angiotensin-receptor blockers (ARBs) are prescribed to control blood pressure (BP).
|
09/2009 |
9-4 |
Diabetes Clinical Practice Guidelines:
Could Changing the Message Change Care?
ONIL BHATTACHARYYA, MD, PHD, CCFP, AND ELIZABETH ESTEY, MA
The prevalence of diabetes is rising, which increases the burden on the healthcare system, and most of this burden is handled in primary-care settings. As a result, primarycare providers face many competing priorities, with diabetes often only one of several problems addressed in a patient visit.
|
08/2009 |
9-3 |
Familial Hypercholesterolemia: Why every
endocrinologist should know about PCSK9
PHILIP W. CONNELLY, PHD
Familial hypercholesterolemia is an established cause of cardiovascular disease. This issue of Endocrinology Rounds presents the background for the discovery of the defects in cellular cholesterol uptake that were first described in this disorder, summarizes the latest recommendation for identifying familial hypercholesterolemia, and discusses the insights from the most recent discovery of the role for PCSK9 in cholesterol metabolism.
|
07/2009 |
9-2 |
Diabetes, Osteoporosis, and Fractures
BY ROBERT G. JOSSE , MD, FRCPC
For some time it has been recognized that people with diabetes are at increased risk for fracture, especially peripheral fractures. Type 1 diabetes mellitus (T1DM tends to be associated with reduced bone density (BMD), whereas in type 2 diabetes(T2DM) the BMD is normal or increased, yet fractures still occur.
|
01/2009 |
9-1 |
Renal Sodium Glucose Transport Inhibition
for the Treatment of Type 2 Diabetes
BY LOREN D. GROSSMAN, MD, FRCPC, FACP
Despite a plethora of therapeutic options for the treatment of type 2 diabetes mellitus (T2DM), the ability to normalize glucose levels and reduce long-term complications of diabetes with treatment remains elusive. From the discovery of insulin in the early 1920s to the incretins of the last few years, as well as all the other developments in between, the ideal antidiabetes medication has not yet been revealed.
|
12/2008 |
8-10 |
Adrenal Cancer: Effective Detection, Staging, and Management
By JASON GALANOS, MB, Bs(Hons), FRACP
Adrenocortical carcinoma (ACC) is a rare, highly malignant tumour with a poor prognosis. ACC may present with symptoms and signs of hormone excess, symptoms related to tumour growth, or as an incidental adrenal lesion discovered on imaging studies.
|
11/2008 |
8-9 |
The 2008 Canadian Diabetes Association Clinical Practice Guidelines: Focus on Cardiovascular Disease
By ALICE Y.Y. CHENG, MD, FRCPC
The Canadian Diabetes Association (CDA) 2008 Clinical Practice Guidelines (CPGs) for the prevention and management of diabetes mellitus (DM) in Canada were published in September. This set of guidelines represents an updated version and, when compared to its predecessor in 2003, is greater in breadth, scope, and length.
|
10/2008 |
8-8 |
Diabetic Ketoacidosis: Challenging Cases
By JEANNETTE GOGUEN, MD, and MARTIN SCHREIBER, MD
Diabetic ketoacidosis (DKA) is a hyperglycemic emergency that occurs in Type 1 diabetes mellitus (T1DM) and only very rarely in Type 2 DM. The incidence of DKA is reported to be 4.6-12.5 per 1000 diabetic persons per year.
|
09/2008 |
8-7 |
Obesity, insulin resistance, and type 2
diabetes: the fat-muscle connection
By M. CONSTANTINE SAMAAN, MD, MRCPI, MRCPCH and AMIRA KLIP, PhD
Type 2 diabetes mellitus (T2DM) and obesity are two global epidemics that show no signs of abating. The number of adults with impaired glucose tolerance (IGT) and T2DM is predicted to continue rising over the coming few decades. In children, in addition to the steady overall rise in rates of overweight, obesity, and T2DM, certain groups are identified as having a particularly high risk of developing IGT and T2DM.
|
08/2008 |
8-6 |
Cystic Fibrosis-Related Diabetes – An Update
By CATHERINE YU, MD
The prevalence of cystic fibrosis-related diabetes (CFRD) has increased in parallel with the improved survival of patients with CF. Although initially thought to be benign, the emergence of microvascular complications, as well as an association with declining pulmonary function and increased mortality has shifted the assessment of CFRD.
|
06/2008 |
8-5 |
Beta-Cell Insulin Resistance Contributes to Onset of Diabetes
By QINGHUA WANG, MD, PhD
Insulin is a ubiquitous growth factor that regulates cell proliferation, gene expression, protein synthesis, and cell survival in most mammalian tissues. Recent studies indicate that insulin plays an important role in regulating islet beta-cell growth and function.
|
06/2008 |
8-4 |
Stem Cell Strategies for Pancreatic ?-cell
Regeneration: From Bench to Bedside
By XIAOHONG WU, MD, PhD, and MINNA WOO, MD, PhD
Pancreatic ? cells are exquisite endocrine cells that control glucose homeostasis. Under physiological conditions, mammals maintain a dynamic ?-cell mass throughout life in response to various demands for insulin. Critical ?-cell mass is kept in delicate balance by ?-cell replication, neogenesis, hypertrophy, and apoptosis.
|
04/2008 |
8-3 |
Smoking Cessation and Diabetes
By PETER SELBY, MBBS, CCFP, FASAM
Nicotine, when inhaled through the combustion of tobacco, is the most addictive drug known to mankind. One in five Canadians smoke cigarettes. The association between smoking and disorders such as cardiovascular (CV) and respiratory diseases, and carcinoma is well known; however, most clinicians and smokers are unaware of the association between smoking and the risk of developing type 2 diabetes mellitus (T2DM).
|
02/2008 |
8-2 |
The Glycemic Index in the Management of Obesity
By THOMAS M.S. WOLEVER, BM, BCh, PhD, DM
This issue of Endocrinology Rounds discusses the role of dietary carbohydrates (CHOs) and the glycemic index in the management of body weight. It is commonly thought that diets eliciting low blood-glucose responses enhance weight loss by increasing satiety and fat oxidation.
|
01/2008 |
8-1 |
Environment and Obesity: Where You Live Matters
By GILLIAN BOOTH, MD, FRCPC
As in other areas of the world, the past two decades have seen a substantial rise in the prevalence of obesity in Canada. More than 50% of Canadian adults are now overweight and the prevalence of overweight and obesity among Canadian children has nearly quadrupled since the 1980s.
|
11/2007 |
7-10 |
The Use of Metformin in Pregnancy
By MARIA KRAW, MD
Metformin is an oral medication currently approved for the treatment of type 2 diabetes. Its off-label use in the treatment of anovulation associated with polycystic ovary syndrome (PCOS) has been supported by several studies and systematic reviews.
|
11/2007 |
7-9 |
Perioperative Management of the Pituitary Patient
By JEANNETTE GOGUEN, MD
Managing a patient requiring pituitary surgery involves a multidisciplinary approach that includes the neurosurgeon, ENT surgeon, anesthesiologist, ophthalmologist, and endocrinologist. This issue of Endocrinology Rounds discusses the perioperative management of these patients from an endocrinology point of view, with particular emphasis on indications for surgery, evaluation of the need for perioperative glucocorticoid replacement, and postoperative assessment of water balance disorders.
|
10/2007 |
7-8 |
Do Fibrates Have a Role in Reducing Cardiovascular Disease in Diabetes?
By ALICE Y.Y. CHENG, MD, FRCPC
Cardiovascular disease (CVD) remains the leading cause of death among individuals with diabetes mellitus (DM) and, as a result, there continues to be a strong focus on therapies to further reduce CV outcomes. The peroxisome proliferator-activated receptor (PPAR) family of ligand-activated transcription factors has been a popular therapeutic target for many years because of its multiple roles in lipid and glucose metabolism and vascular biology.
|
09/2007 |
7-7 |
New Treatment Modalities for Osteoporosis
By SOPHIE JAMAL, MD, PhD
Over the past decade, there have been many advances in the treatment of osteoporosis and related fractures. For example, Health Canada recently approved the second-generation bisphosphonate, risedronate, for monthly administration, and now, patients with osteoporosis can be offered treatment with the anabolic agent, parathyroid hormone.
|
08/2007 |
7-6 |
HAART-Associated Lipodystrophy:
A Practical Approach
By CATHERINE YU, MD
Since its emergence in 1981, human immunodeficiency virus (HIV) infection has become a global pandemic. With HIV came the devastating consequences of severe immunodeficiency, including Pneumocystis jiroveci (carinii) pneumonia, progressive multi -
focal leukoencephalopathy, and disseminated Mycobacteria avium complex (MAC) infection.
|
06/2007 |
7-5 |
Glaucoma and Diabetic Eye Disease:
Neuroprotection and Preserving Sight
By NEERU GUPTA, MD, PhD, FRCSC, and EFREM MANDELCORN, MD
Glaucoma and diabetic retinopathy are major causes of irreversible blindness worldwide. Treatment of glaucoma involves the medical and surgical reduction of pressure within the eye, while treatments for diabetic retinopathy relate to the effects of blood vessel pathology and proliferation in the eye.
|
05/2007 |
7-4 |
The Incidental Adrenal Lesion:
The Approach to Imaging Evaluation
By WALTER MAK, MD, FRCPC, and LOUIS WU, MD, CM, FRCPC
The so-called adrenal “incidentaloma,” referring to lesions detected during radiologic evaluation for disease unrelated to the adrenal gland, is a clinical scenario being encountered with increasing frequency as utilization of cross-sectional imaging increases in routine clinical practice. Adrenal lesions >1 cm have been noted on up to 4.4% of computed tomography (CT) scans performed for unrelated indications.
|
04/2007 |
7-3 |
Novel GLP-1 Fusion Peptides as Potential Therapies for the Prevention and Treatment of Diabetes
By Qinghua Wang, MD, PhD
Regulation of glucose homeostasis is a complex physiological process that requires the actions of numerous hormones. One such important hormone is glucagon-like peptide-1 (GLP-1), an incretin released from endocrine L-cells in the gastrointestinal mucosa in response to nutrient ingestion.
|
03/2007 |
7-2 |
Intervening in the Pathway of Beta Cell Destruction in Type 1 Diabetes
By NATASHA RAZACK, MPH, and DIANE WHERRETT, MD, FRCP
Significant advances in understanding the pathogenesis of type 1 diabetes mellitus (T1DM) have led to a multitude of opportunities for intervention. Specifically, a more thorough understanding has evolved of the potential for primary prevention efforts and betacell preservation strategies at the time of diagnosis.
|
01/2007 |
7-1 |
Menopause, Hormones, and the
Critical Therapeutic Window
By CHRISTINE M. DERZKO, MD, FRCSC
A decade ago, the prevailing opinion was that postmenopausal hormone therapy reduced coronary heart disease (CHD) by 30%-50%. This position was based on a vast body of evidence, including the results from several large, prospective, observational studies, epidemiological studies, and a variety of randomized controlled trials (RCTs) using surrogate markers.
|
12/2006 |
6-10 |
Comparing Mythologies: Perspectives on the Utility of Continuous Glucose Monitors in Diabetes Care
By BRUCE A. PERKINS, MD, MPH, FRCPC
The Diabetes Control and Complications Trial and its subsequent observations unequivocally demonstrated the importance of better glycemic control for reducing the risk of chronic complications in the type 1 diabetes population.
|
11/2006 |
6-9 |
Thyroid Autoimmunity and Reproduction
By MARIA KRAW, MD
Autoimmune thyroid disease (AITD) is characterized by the presence of antithyroid antibodies, specifically antibodies to thyroglobulin and thyroid peroxidase. These antibodies have been reported in 5%-10% of reproductive-aged women, making AITD the most common autoimmune disorder affecting this population. Although the most frequent cause of thyroid failure (overt or subclinical hypothyroidism), AITD can present without thyroid dysfunction and, thus, remains undiagnosed.
|
10/2006 |
6-8 |
Pituitary Apoplexy:
Dont Miss the Diagnosis!
By JEANNETTE GOGUEN, MD
Pituitary apoplexy is a rare and potentially lethal endocrine and neurosurgical emergency. It is often misdiagnosed or diagnosed late in its course. The purpose of this issue of Endocrinology Rounds is to review the pathophysiology of pituitary apoplexy and discuss how to confirm the diagnosis in a timely manner.
|
09/2006 |
6-7 |
Current controversies in the use of
radioactive-iodine remnant ablation in
well-differentiated thyroid carcinoma
By ANNA M. SAWKA, MD, PhD, FRCPC
Radioactive-iodine remnant ablation (RRA) is commonly performed as adjuvant therapy in the treatment of well-differentiated thyroid cancer. There is no long-term, randomized, controlled trial evidence to support the use of this intervention.
|
07/2006 |
6-6 |
Pathology of Adrenocorticotropic
Hormone Excess
By KALMAN KOVACS, MD, and FATEME SALEHI
Adrenocorticotropic hormone (ACTH) excess may give rise to severe clinical symptoms and marked laboratory alterations that, if not properly treated, can lead to irreversible organ damage and patient death.
|
05/2006 |
6-5 |
Dietary Treatment of Dyslipidemia:
Overlooked and Undervalued?
By DANA WHITHAM, MSc, RD, CDE
According to the Canadian Heart Health Survey, 36% of Canadian adults have an atherogenic lipid profile. Many, including some at low risk, are treated with medications. Among patients with diabetes in Canada, 59% have dyslipidemia, as well as other co-morbid conditions.
|
04/2006 |
6-4 |
Gene Transfer for the Prevention or Treatment of Type 1 Diabetes
BY GÉRALD J. PRUDHOMME, MD, FRCPC
The endocrine organs are frequently the targets of autoimmunity due to a breakdown in immune tolerance. Rarely, this occurs in the thymus due to mutations in the autoimmune regulator (AIRE) gene and results in the failure to eliminate thymocytes, which react strongly to self-antigens (insulin and many others).
|
03/2006 |
6-3 |
Facts and Fiction of a Diabetes Diet
By DANA WHITHAM, RD, MSC, CDE
Nutrition therapy is considered an essential component of diabetes management, yet people with diabetes are often given advice that is not based on scientific evidence. Since most individuals get their nutritional information from television and magazines, and not a physician or dietitian, many myths and misconceptions abound.
|
02/2006 |
6-2 |
Diagnosing Hyperandrogenism in Women
By MARIA KRAW, M.D.
All women produce androgens in their adrenal glands and ovaries. Androgens have important physiological effects in women through their direct effects on androgen receptors and as precursors for estrogen biosynthesis.
|
01/2006 |
6-1 |
New Insights on the Regulation of Glucagon Secretion from Islet Alpha Cells and its Importance in Diabetes
By QINGHUA WANG, MD, PhD
Diabetes is the leading cause of death from disease in North America and, in Canada alone, over 2 million people have diabetes. Hyperglycemia is the characteristic sign of diabetes and a predominant cause of the development of the long-term complications associated with the disease.
|
12/2005 |
5-10 |
Targeting Low HDL Recent Developments
BY DOMINIC S. NG, PhD, MD
The inverse relationship between the plasma high-density lipoprotein cholesterol (HDL-C) and risk of coronary heart disease (CHD) is well-recognized in the general population.
|
11/2005 |
5-9 |
Cancer Treatment-induced Bone Loss
By ROBERT G. JOSSE , MD, FRCPC
Cancer is the leading cause of death among younger women aged 30 to 54 years, with breast cancer comprising 28% of all cancers in females per year. One in 8 women will develop breast cancer during her lifetime.
|
10/2005 |
5-8 |
Pancreatic Islet Cell Transplantation in the Treatment of Type 1 Diabetes Mellitus
By AMISH PARIKH, MD, FRCPC
Pancreatic islet cell transplantation as a treatment modality for type 1 diabetes mellitus (T1 DM) has garnered renewed interest and research over the past few years as a result of advances in the field of transplantation.
|
09/2005 |
5-7 |
Incretin-Based Therapies for the Treatment
of Type 2 Diabetes
By LOREN D. GROSSMAN, MD, FRCPC, FACP
Since the discovery of insulin over 80 years ago, research has sought better ways to help people with diabetes mellitus (DM) control their disease. Although glucose control for type 1 DM is addressed with insulin alone, for type 2 DM, in addition to insulin, numerous classes of oral antihyperglycemic agents exist.
|
07/2005 |
5-6 |
The Clinical Utility of Bone Mineral Density Testing to Identify Men and Women at Risk for Fracture
By SOPHIE A. JAMAL, MD, PhD and ROBERT G. JOSSE, MD
Osteoporosis has been traditionally defined as a systemic skeletal disease characterized by low bone mass and micro-architectural deterioration of bone tissue with a resultant increase in fragility and risk of fracture.
|
06/2005 |
5-5 |
Alternative Medicine for Glycemic Control in Type 2 Diabetes Mellitus: Whats the Evidence?
By JEANNETTE GOGUEN, MD
This issue of Endocrinology Rounds reviews the best available evidence about the impact of alternative medications on glycemic control. Alternative medicine has been used to treat diabetes mellitus (DM) for thousands of years.
|
04/2005 |
5-4 |
Long-acting insulin analogues
By AMIR HANNA, MB, BCh, FRCPC, FACP
More than 80 years ago, the discovery of insulin in Canada was a landmark event that changed the face of diabetes treatment. Insulin gave life to people with type 1 diabetes mellitus (T1 DM) who, until then, succumbed to their disease. Presently, millions of people use insulin for the treatment of T1 and T2 DM.
|
03/2005 |
5-3 |
Male Osteoporosis
By SOPHIE JAMAL, M.D., Ph.D., FRCPC
Over the past few years, our understanding of osteoporosis has shifted.We no longer consider it a disease exclusively in postmenopausal women, but have come to realize that it can affect men as well.
|
02/2005 |
5-2 |
Will Tomatoes Prevent Osteoporosis?
By LETICIA G. RAO, Ph.D.
Osteoporosis is a major metabolic bone disease that occurs primarily in women over the age of 50 because of the loss of estrogen during menopause. Oxidative stress as a risk factor for osteoporosis has garnered a lot of interest.
|
01/2005 |
5-1 |
Type 2 Diabetes Mellitus: Focusing on Insulin Action from a Cellular Perspective
By MINNA WOO, M.D., Ph.D.
The incidence of type 2 diabetes mellitus (T2 DM) is increasing at an alarming rate. The human genome has evolved to include sophisticated genes that enable us to store fuel in a highly efficient manner.
|
12/2004 |
4-10 |
Beneficial Effects of Exercise in Type 2 Diabetes Mellitus
By PAUL OH, MD, FRCPC, FACP; NICOLE FOSTER, MSc; and CATHERINE STATTON, BSc
Physical activity is a well-established and important therapeutic modality for persons with type 2 diabetes mellitus (T2 DM). Regular exercise improves conventional risk factors, cardiovascular fitness, insulin resistance, and glycemic control.
|
11/2004 |
4-9 |
Osteopenia What it means and when to treat
By SOPHIE A. JAMAL, MD, PhD, FRCPC
Over the past 10 years, several large trials have established the importance of identifying and treating postmenopausal women with osteoporosis.
|
10/2004 |
4-8 |
Surgical Management of Adrenal Disorders: The Triumph of Minimally-invasive Surgery
By KENNETH PACE, MD, MSC, FRCSC
There has been a revolution in surgical practice over the last decade that has seen minimally-invasive surgical techniques applied to a broad range of operative procedures. Adrenalectomy is one example of the dramatic benefits that laparoscopic surgery can offer patients, while replicating the benefits of open surgery.
|
09/2004 |
4-7 |
Intestinal Absorption Inhibitors in the Prevention and Treatment of Type 2 Diabetes Mellitus
By ALICE Y.Y. CHENG, MD, FRCPC, and ROBERT G. JOSSE, MBBS, FRCPC
Type 2 diabetes mellitus (T2DM) is a complex metabolic disorder resulting from peripheral insulin resistance and relative insulin deficiency secondary to dysfunctional pancreatic beta cell secretion of insulin.
|
06/2004 |
4-6 |
Using Insulin Effectively in the Management of Diabetes
By RAVI RETNAKARAN, MD, FRCPC, and BERNARD ZINMAN, MDCM, FRCPC, FACP
Since its discovery and first therapeutic use on January 11, 1922 at the Toronto General Hospital, insulin has been a life-saving therapy for type 1 diabetes and an important option for managing type 2 diabetes.
|
05/2004 |
4-5 |
Diabetes Mellitus and Renal Transplantation
By G.V. RAMESH PRASAD, MBBS, MSC, FRCPC, FACP
Diabetes mellitus after renal transplantation consists of both pre-existing diabetes and new-onset diabetes or NODM. Previously the term post-transplant diabetes mellitus or PTDM was used; however, this condition is distinct from pre-existing diabetes and may have its own underlying pathophysiology and clinical course.
|
04/2004 |
4-4 |
Carboxylterminal Receptor for Parathyroid Hormone and Circulating C-terminal PTH Ligands: Current Knowledge and Clinical Relevance
By TIMOTHY M. MURRAY, MD, FRCPC
Parathyroid hormone (PTH) is the major regulator of serum calcium homeostasis. It is an 84 amino acid peptide hormone, secreted in response to hypocalcemia. It restores normocalcemia through a negative feedback loop mediated by the calcium-sensing receptor on parathyroid chief cells.
|
03/2004 |
4-3 |
New Progress in Type 1 Diabetes:
Hopes for the Future
By MINNA WOO, MD, FRCPC, PhD
Type 1 diabetes is a chronic, polygenic, autoimmune disease that acts selectively against insulin-producing pancreatic ß cells. Despite its chronic nature, little is clinically apparent until the disease reaches the end-stage and the ß cells are almost entirely eliminated.
|
02/2004 |
4-2 |
Challenges in Diagnosing Pheochromocytoma
By JEANNETTE GOGUEN, MD, MED, FRCPC
A pheochromocytoma is a tumour of chromaffin cells of the sympathetic nervous system. Due to its propensity to produce and secrete catecholamines, this disease usually presents with hypertension and other symptoms of catecholamine excess.
|
01/2004 |
4-1 |
Patterns and Outcomes of Diabetes in Canada studied using Administrative Data: The Ontario experience
By GILLIAN BOOTH, MD
Diabetes mellitus (DM) is a serious and growing health problem. Approximately 6% of Canadian adults have been diagnosed with DM; however, with the aging of the population and growing rates of obesity, the number of people with this condition is expected to rise.
|
12/2003 |
3-10 |
Hypoglycemic Disorders
By AMIR HANNA, MB, BCH , FRCPC, FACP
A fine balance between glucose production and glucose utilization maintains glucose levels in the normal range, both in the fasting and the fed states.
|
11/2003 |
3-9 |
Type 2 Diabetes Mellitus in Youth: An emerging epidemic
By AMISH PARIKH, MD
Type 2 diabetes mellitus (DM) is now a worldwide epidemic. As a consequence, its prevention is one of the most important contemporary public health concerns. It is estimated that, worldwide, 225 million cases of Type 2 DM will be diagnosed by the end of the present decade and as many as 300 million cases by the year 2025.
|
10/2003 |
3-8 |
Polycystic Ovarian Syndrome
By SHELLY BHAYANA, MD
Polycystic ovarian syndrome (PCOS) is one of the most common endocrine disorders affecting women, occurring in up to 10% of the female population.
by symptoms of menstrual irregularity and hyperandrogenism.
|
08/2003 |
3-7 |
The effects of declining ß-cell mass in the development of diabetes
By QINGHUA WANG M.D., PH.D.
Over 2 million Canadians have diabetes and numerous epidemiologic studies indicate that the prevalence of prediabetic and diabetic populations will continue to increase both in Canada and worldwide.
|
06/2003 |
3-6 |
Gestational diabetes mellitus: What does it predict for the future?
RAVI RETNAKARAN, MD
Gestational diabetes mellitus (GDM), is defined as glucose intolerance of varying severity with onset or first recognition during pregnancy. It is a common condition affecting 2%-3% of all pregnant women.
|
05/2003 |
3-5 |
Lipoprotein (a)
A complex risk factor for coronary heart disease
PHILIP W. CONNELLY, PhD.
This issue of Endocrinology Rounds reviews the evidence for using lipoprotein (a) [Lp(a)] to assess cardiovascular risk and guide therapeutic decisions in primary and secondary prevention.
|
04/2003 |
3-4 |
Parathyroid hormone treatment of osteoporosis
TIMOTHY M. MURRAY, MD, FRCPC
Parathyroid hormone (PTH) has historically been known as a bone resorbing hormone mainly because of its negative effects on bone in primary hyperparathyroidism and in secondary hyperparathyroidism associated with chronic renal failure.
|
03/2003 |
3-3 |
Cystic fibrosis-related diabetes
AMIR HANNA, MB, BCH, FRCPC, FACP
Cystic fibrosis (CF) is the most common severe autosomal recessive disease in Caucasians with an incidence of 1/3000 live births.1 Patients have a mutation of the CF transmembrane conductance regulator gene on chromosome 7 and about 70% have a 3-base pair deletion ∆F508.
|
02/2003 |
3-2 |
Fractures in men and women with dialysis-dependent renal failure
Sophie Jamal, MD
The number of Canadians with dialysis-dependent renal failure (DDRF) is increasing. In 1996, approximately 11,000 Canadians were being treated with hemodialysis or peritoneal dialysis and this number is projected to climb to approximately 20,000 by the year 2005.
|
01/2003 |
3-1 |
Management of prolactinomas
KIMBERLY A. MAH-POY, MD
Prolactinomas are one of the most common hormone-secreting pituitary tumours. They are a primary cause of hyperprolactinemia.
|
12/2002 |
2-10 |
Combination lipid-lowering therapy in type 2 diabetes mellitus: A review of the evidence
JEANNETTE M. GOGUEN, MD, FRCPC
Current lipid-lowering guidelines have stringent targets for LDL-cholesterol (LDL-C), triglyceride (TG), and HDL-cholesterol (HDL-C) levels in patients with type 2 diabetes mellitus (DM).
|
11/2002 |
2-9 |
Subclinical hypothyroidism
By WILLIAM SINGER, MD
Hypothyroidism is a common condition with slowly progressive nonspecific symptoms. It is often diagnosed serendipitously and occurs most frequently in women over 50.
|
10/2002 |
2-8 |
Antiplatelet therapy in diabetes
MARIA KRAW, M.D.
Cardiovascular disease (CVD) remains a major cause of morbidity and mortality in diabetes. Patients with type 2 diabetes have a 2- to 4-fold increased risk of CVD that is present even before the development of fasting hyperglycemia.
|
08/2002 |
2-7 |
Growth hormone replacement for adult-onset
growth hormone deficiency What have we learned?
MONIQUE PIERSANTI, MSC, MD, FRCPC
With the introduction of recombinant growth hormone (rhGH) in 1985, the possibility of replacement therapy for a number of clinical scenarios became possible.
|
06/2002 |
2-6 |
Targets for glycemic control: What is the evidence?
GILLIAN BOOTH, MD
A causal relationship between high glucose levels and the chronic complications of diabetes was postulated long before the results of recent studies illustrating the benefits of intensive glycemic control.
|
05/2002 |
2-5 |
Dietary carbohydrate in the management of diabetes: importance of source and amount
THOMAS M. S. WOLEVER, PhD, MD
It is generally agreed that a cornerstone for managing diabetes is diet, but there is considerable controversy about what is the best kind of dietary advice.
|
04/2002 |
2-4 |
The pathogenesis of the chronic complications of diabetes mellitus
I. GEORGE FANTUS, MD
Diabetes mellitus is currently defined as blood glucose concentrations that are elevated above normal.
|
03/2002 |
2-3 |
Perioperative glycemic control:
What is the evidence?
ALICE Y.Y. CHENG, MD
Surgery in the patient with diabetes mellitus is relatively common because diabetes predisposes to certain medical conditions that require surgical intervention.
|
02/2002 |
2-2 |
Celiac disease and osteoporosis:
A frequent but unrecognized association
TIMOTHY M. MURRAY, MD, FRCPC
Over the past decade, the introduction of new serological tests for celiac disease has dramatically increased the frequency of its diagnosis, resulting in considerable changes in our clinical perspective of this disease.
|
01/2002 |
2-1 |
Recent advances in the treatment of low HDL: In search of novel therapeutics
DOMINIC NG, PhD, MD
The notion that high-density lipoprotein (HDL) is protective of the development of coronary heart disease (CHD) dates back to the early observation of the inverse relationship between plasma HDL-cholesterol (HDL-C) levels and the prevalence of CHD in the 1950s.
|
12/2001 |
1-2 |
Osteoporosis in men
ROBERT G. JOSSE, MD
Osteoporosis was once thought inappropriately to be an inevitable consequence of aging.
|
11/2001 |
1-1 |
Combination therapy with oral hypoglycemic agents: Rationale and principles
AMIR K. HANNA, MB, BCH , FRCPC, FACP
The objective of this inaugural issue of Endocrinology Rounds is to review the impact of intensive and early glucose control on the complications of diabetes, understand the characteristics of the different classes of oral hypoglycemic agents, highlight the benefits of combination therapy with oral hypoglycemic agents, and provide an overview of recent combination therapy studies.
|
Total: 77 |
